Home › About ›
Ilan brings over 20 years of multinational managerial and corporate experience with pharmaceutical and high-tech companies. Ilan has been instrumental in building companies from start-ups to hundreds of millions of dollars in operations. He successfully took part in the development, approval, and launch of new pharmaceutical products in the U.S. and Israel. Ilan has also been responsible for leading the operations, R&D, manufacturing, regulatory, and corporate finance for premier healthcare companies in the U.S. and Israel.
Prior to joining PainReform, Ilan served as Country Manager Israel and CFO at Foamix Pharmaceuticals Ltd. (now NASDAQ: VYNE) since 2014, where he was instrumental in building the organization and launching new innovative topical drugs in the U.S., as well as a focus on capital markets and M&A. Prior to Foamix, Ilan was Finance Director at Pfizer Pharmaceutical Ltd., where he oversaw all commercial, financial and operational activities of the local entity. Prior to that, Ilan served as Finance Manager at HP Indigo Ltd, a world-leading company in digital printing. Prior to that, Ilan was Finance Director at BAE Systems (FTSE:BA), the third-largest defence company in the world, where he was responsible for all financial activities of BAE Systems Israel. From 1998 to 2016, Ilan was Chief Financial Officer at Mango DSP, a global leader of Intelligent Video Solutions, where he was successful in building the company from the incubator stage to a multinational, multi-million dollar revenue-generating company. Ilan serves on the Board of Directors at Kadimastem, a public Israeli biopharmaceutical company (TASE: KDST). Ilan received his MBA in Finance and Business Entrepreneurship and B.A. degree at The Hebrew University in Jerusalem, Israel.
Eli brings diverse expertise from both the healthcare industry and academia. He has been a general partner with Medica VC since 1995. prior to joining Medica, Eli spent 5 years at Glaxo Inc. at the Research Triangle Park, NC, as Head of the Department of Receptor Research and Metabolic Diseases, and as a member of the Corporate Committee for New Technology Identification. Upon returning to Israel, Eli served in various executive research and development positions at Biotechnology General Corp. (Savient) and as VP R&D at Peptor Ltd. Over the last 15 years Eli has taken leadership roles within Medica portfolio companies including interim CEO for Collgard Biopharmaceuticals and Ester Neurosciences, where he was responsible for executing Ester’s acquisition by Amarin Pharmaceuticals.
Eli received his Ph.D. degree from the Weizmann Institute of Science in 1978 based on research in the field of hormone biochemistry, and has an executive MBA from Humberside University in the UK. He is the author of more than 100 scientific publications and patents in various areas of drug development.
Sigal brings 15 years of managerial experience in the Biotech industry. Prior to joining PainReform Sigal held the position of Chief R&D Officer at MediWound, a company specializing in deep burns and chronic wound care, where she was responsible for product development from early stages to final product approval by regulatory authorities. Previously she served as a VP of clinical and regulatory affairs at Biokine LTD focusing on cancer therapy. Formerly she directed both platform and project development at Protalix Biotherapeutics while managing a large group of scientists on projects ranging from autoimmune diseases to chemical warfare and genetic diseases.
Sigal holds a PhD in Immunology and Microbiology from Duke University Medical School as well as an executive MBA degree from the Kellogg school of business at NW University. She did her postdoctoral work with Nobel laureate Prof. Aaron Ciechanover.